Navidea gets 5-year patent extension for Lymphoseek

By staff writers

March 20, 2020 -- Radiopharmaceutical developer Navidea Biopharmaceuticals has received a five-year patent extension for its Lymphoseek radiopharmaceutical.

The U.S. Patent and Trademark Office has extended the duration of U.S. patent No. 6,409,990 until May 12, 2025, according to Navidea.

The patent covers the technology behind Lymphoseek, a technetium-based radiopharmaceutical that has been licensed to Cardinal Health. The extension allows Cardinal Health and Navidea to extend their exclusive rights to manufacture and commercialize Lymphoseek until the end of the extended patent date, according to the company.

Copyright © 2020

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking